La Merie Publishing is an independent business information provider for the biotechnology and pharmaceutical industry. We publish proprietary reports and prepare custom reports.
Claudin 18.2: a clinically validated target and plenty of improvement options with new drug modalities – a pipeline review STUTTGART, Germany I September 25, 2025 I La Merie Publishing announced the release of its newest product offering reviewing the pipeline of active therapy candidates in research and development targeting claudin...
PD-L1 and 4-1BB (CD137): promising immuno-oncology therapy combination to overcome on-target-off-tumor toxicity – a pipeline review STUTTGART, Germany I September 24, 2025 I La Merie Publishing announced the release of its newest product offering reviewing the pipeline of active therapy candidates in research and development targeting CD47 or SIRPα: Pipeline...
CD47 and SIRPα: next generation inhibitors to show clinical benefit – a pipeline review STUTTGART, Germany I September 23, 2025 I La Merie Publishing announced the release of its newest product offering reviewing the pipeline of active therapy candidates in research and development targeting CD47 or SIRPα: Pipeline of CD47...
Complement C5: a commercially successful and clinically effective treatment of C5 mediated diseases – a pipeline review STUTTGART, Germany I September 22, 2025 I La Merie Publishing announced the release of its newest product offering reviewing the pipeline of active therapy candidates in research and development targeting the complement C5...
IL-6 and IL-6R: hot targets for underexploited indications – a pipeline review STUTTGART, Germany I September 09, 2025 I La Merie Publishing announced the release of its newest product offering reviewing the pipeline of active IL-6R antagonists and IL-6 inhibitors in R&D: Pipeline of Interleukin-6 (IL-6) Receptor Antagonists and IL6-...
CD40 and CD40L: a versatile target as co-stimulator in cancer and for antagonism in autoimmune diseases – a pipeline review STUTTGART, Germany I September 09, 2025 I La Merie Publishing announced the release of its newest product offering reviewing the pipeline of active CD40 agonists and CD40/L antagonists in R&D:...
CD73: a novel checkpoint protein STUTTGART, Germany I September 08, 2025 I La Merie Publishing announced the release of its newest product offering reviewing the pipeline of active CD73 inhibitors in R&D: Pipeline of CD73 Inhibitors. This competitive intelligence report about CD73 Inhibitors provides an up-to-date competitor evaluation in the...
IGF-1R: a validated thyroid eye disease target and a re-emerging cancer target – a pipeline review STUTTGART, Germany I September 05, 2025 I La Merie Publishing announced the release of its newest product offering reviewing the pipeline of active anti-IGF-1(R) immunotherapies in R&D: Pipeline of IGF-1R- and IGF-1 Targeted Immunotherapy....
NaPi2b: a viable solid tumor target for novel ADC technologies – a pipeline review STUTTGART, Germany I September 04, 2025 I La Merie Publishing announced the release of its newest product offering reviewing the pipeline of active anti-NaPi2b immunotherapies in R&D: Pipeline of NaPi2b-Targeted Immunotherapies. This competitive intelligence report about...
FcRn: a commercially and clinically validated target in a variety of antibody-mediated autoimmune diseases – a pipeline review STUTTGART, Germany I September 03, 2025 I La Merie Publishing announced the release of its newest product offering reviewing the pipeline of active anti-FcRn therapeutics in R&D: Pipeline of FcRn-Targeted Therapies. This...
